Treatment of chronic hepatitis C : Combination therapy permanently eradicates the virus in at least 40% of patients

Por Davis, Gary L
Publicado em 2001

Gary L. Davis, MD: a conversation with the editor

Por Davis, Gary L.
Publicado em 2003

Hepatitis C virus replication and potential targets for direct-acting agents

Por O’Leary, Jacqueline G., Davis, Gary L.
Publicado em 2010

Use of Protease Inhibitors in Liver Transplant Recipients

Por Davis, Gary L., O'Leary, Jacqueline G.
Publicado em 2012

The prevalence of hepatitis C virus infection in Texas: implications for future health care

Por Yalamanchili, Kanthi, Saadeh, Sherif, Lepe, Rita, Davis, Gary L.
Publicado em 2005

Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants

Por O’Leary, Jacqueline G., Landaverde, Carmen, Jennings, Linda, Goldstein, Robert M., Davis, Gary L.
Publicado no Clin Gastroenterol Hepatol (2011)

Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined

Por O’Leary, Jacqueline G., Neri, Michael A., Trotter, James F., Davis, Gary L., Klintmalm, Göran B., Annette, C., Simmons, Harold C.
Publicado no Transpl Int (2012)

Effect of tacrolimus on survival in hepatitis C–infected patients after liver transplantation

Por O'Leary, Jacqueline G., Trotter, James F., Neri, Michael A., Jennings, Linda W., McKenna, Greg J., Davis, Gary L., Klintmalm, Göran B.
Publicado em 2011

Hepatocellular carcinoma: management of an increasingly common problem

Por Davis, Gary L., Dempster, Jane, Meler, James D., Orr, Douglas W., Walberg, Mark W., Brown, Brian, Berger, Brian D., O'Connor, John K., Goldstein, Robert M.
Publicado em 2008